DK0598029T3 - Retrovirale vektorer indeholdende interne ribosome indgangssteder - Google Patents

Retrovirale vektorer indeholdende interne ribosome indgangssteder

Info

Publication number
DK0598029T3
DK0598029T3 DK92917724T DK92917724T DK0598029T3 DK 0598029 T3 DK0598029 T3 DK 0598029T3 DK 92917724 T DK92917724 T DK 92917724T DK 92917724 T DK92917724 T DK 92917724T DK 0598029 T3 DK0598029 T3 DK 0598029T3
Authority
DK
Denmark
Prior art keywords
ribosome entry
internal ribosome
entry sites
vectors containing
retroviral vectors
Prior art date
Application number
DK92917724T
Other languages
Danish (da)
English (en)
Inventor
W French Anderson
Richard A Morgan
Larry Couture
Original Assignee
W French Anderson
Richard A Morgan
Larry Couture
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24981978&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0598029(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by W French Anderson, Richard A Morgan, Larry Couture filed Critical W French Anderson
Application granted granted Critical
Publication of DK0598029T3 publication Critical patent/DK0598029T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32211—Cardiovirus, e.g. encephalomyocarditis virus
    • C12N2770/32222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Optical Radar Systems And Details Thereof (AREA)
  • Traffic Control Systems (AREA)
  • Fittings On The Vehicle Exterior For Carrying Loads, And Devices For Holding Or Mounting Articles (AREA)
  • Molds, Cores, And Manufacturing Methods Thereof (AREA)
  • Road Signs Or Road Markings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK92917724T 1991-08-07 1992-08-06 Retrovirale vektorer indeholdende interne ribosome indgangssteder DK0598029T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74174091A 1991-08-07 1991-08-07
PCT/US1992/006572 WO1993003143A1 (fr) 1991-08-07 1992-08-06 Vecteurs retroviraux contenant des sites internes d'entree de ribosome

Publications (1)

Publication Number Publication Date
DK0598029T3 true DK0598029T3 (da) 2002-05-27

Family

ID=24981978

Family Applications (1)

Application Number Title Priority Date Filing Date
DK92917724T DK0598029T3 (da) 1991-08-07 1992-08-06 Retrovirale vektorer indeholdende interne ribosome indgangssteder

Country Status (8)

Country Link
EP (1) EP0598029B1 (fr)
JP (1) JP3378962B2 (fr)
AT (1) ATE213779T1 (fr)
CA (1) CA2114416C (fr)
DE (1) DE69232438T2 (fr)
DK (1) DK0598029T3 (fr)
ES (1) ES2173082T3 (fr)
WO (1) WO1993003143A1 (fr)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4228457A1 (de) * 1992-08-27 1994-04-28 Beiersdorf Ag Herstellung von heterodimerem PDGF-AB mit Hilfe eines bicistronischen Vektorsystems in Säugerzellen
DE4228458A1 (de) * 1992-08-27 1994-06-01 Beiersdorf Ag Multicistronische Expressionseinheiten und deren Verwendung
US5589582A (en) * 1992-10-27 1996-12-31 Biotransplant, Inc. Polynucleotides en coding porcine cytokines
BE1006437A3 (fr) * 1992-12-10 1994-08-30 Company S A Z Sequence nucleotidique destinee au traitement du cancer et des infections.
AU6230394A (en) * 1993-01-20 1994-11-21 Biotransplant Incorporated Retroviral vectors capable of expressing multimeric proteins from multiple translational initiation sites
EP0693126B9 (fr) * 1993-04-02 2007-09-12 Rigel Pharmaceuticals, Inc. Procede d'inactivation selective de replication virale
US6824976B1 (en) 1993-04-02 2004-11-30 Rigel Pharmaceuticals, Inc. Method for selective inactivation of viral replication
KR960701988A (ko) * 1993-04-20 1996-03-28 윌리엄 에스. 로빈슨 세포내 감염원에 감염된 개체의 치료방법 및 치료물질(methods and materials for treatment of individuals infected with intracellular in-fectious agents)
GB9320548D0 (en) * 1993-10-06 1993-11-24 Sandoz Ltd Improvements in or relating to organic compounds
GB2284210B (en) * 1993-11-26 1997-11-12 British Tech Group Translational enhancer DNA from a kinesin gene
US6995008B1 (en) 1994-03-07 2006-02-07 Merck & Co., Inc. Coordinate in vivo gene expression
FR2722208B1 (fr) * 1994-07-05 1996-10-04 Inst Nat Sante Rech Med Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique
FR2724320B1 (fr) * 1994-09-13 1996-12-20 Transgene Sa Nouvel implant pour le traitement des maladies acquises
AU780164B2 (en) * 1994-09-13 2005-03-03 Transgene S.A. Novel implant and novel vector for the treatment of acquired diseases
US5518042A (en) * 1994-09-16 1996-05-21 Huyck Licensco, Inc. Papermaker's forming fabric with additional cross machine direction locator and fiber supporting yarns
AT403167B (de) * 1994-11-14 1997-11-25 Immuno Ag Selektion und expression von fremdproteinen mittels eines selektions-amplifikations-systems
DE19514310A1 (de) * 1995-04-18 1996-10-24 Univ Ludwigs Albert Vektoren zur Transfektion von eukaryotischen Zellen, deren Verwendung und damit transfizierte Zielzellen
CA2222879A1 (fr) * 1995-06-02 1996-12-05 M&E Biotech A/S Procede d'identification de peptides et d'acides nucleiques biologiquement actifs
GB9517263D0 (en) * 1995-08-23 1995-10-25 Cancer Res Campaign Tech Expression systems
WO1997014809A2 (fr) * 1995-10-16 1997-04-24 Dana-Farber Cancer Institute Nouveaux vecteurs d'expression et procedes d'utilisation correspondants
GB9524973D0 (en) * 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
US6365344B1 (en) 1996-01-23 2002-04-02 The Board Of Trustees Of The Leland Stanford Junior University Methods for screening for transdominant effector peptides and RNA molecules
US6455247B1 (en) 1996-01-23 2002-09-24 Board Of Trustees Of The Leland Stanford Junior University Methods for screening for transdominant effector peptides and RNA molecules
FR2751345B1 (fr) * 1996-07-16 1998-09-18 Univ Paris Curie Lignees d'encapsidation hautement productrices
FR2755975B1 (fr) * 1996-11-15 1999-05-07 Rhone Poulenc Rorer Sa Virus recombinants bicistroniques utiles pour le traitement de pathologies liees aux dyslipoproteinemies
FR2762615B1 (fr) * 1997-04-28 1999-07-16 Inst Nat Sante Rech Med Nouveau site interne d'entree des ribosomes et vecteur le contenant
AU8105798A (en) * 1997-05-16 1998-12-11 Leuven Research & Development Vzw Mammalian cell transduction for use in gene therapy
EP0938904A1 (fr) * 1998-02-09 1999-09-01 Leuven Research & Development vzw Transduction des cellules mammifères pour utilisation dans la thérapie génique
FI110323B (fi) * 1997-06-02 2002-12-31 Timo Korpela Rekombinanttikonstrukti geenin ilmentämisen lisäämiseksi kasveissa
DE69940521D1 (de) 1998-10-01 2009-04-16 Univ Southern California Retrovirales genübertragungssystem und entsprechendes verwendungverfahren
JP2002542834A (ja) * 1999-04-29 2002-12-17 アールフス・ユニバーシティー レトロウイルスベクターでのｉｒｅｓ転写カセットからの異種遺伝子群の発現
AU2001271614B2 (en) 2000-07-03 2007-05-31 Catalent Pharma Solutions, Llc Host cells containing multiple integrating vectors
AU7025201A (en) 2000-07-03 2002-01-14 Gala Design Inc Expression vectors
US6677500B2 (en) 2000-08-15 2004-01-13 Board Of Trustees Of The University Of Illinois Ungulates expressing exogenous IGF-I in their milk
US7419829B2 (en) 2000-10-06 2008-09-02 Oxford Biomedica (Uk) Limited Vector system
GB0024550D0 (fr) 2000-10-06 2000-11-22 Oxford Biomedica Ltd
ATE466089T1 (de) 2000-12-22 2010-05-15 Agronomique Inst Nat Rech Positionsunabhängige und gewebespezifische expression eines transgens in der milch eines transgen-tieres
US20040038304A1 (en) 2002-03-28 2004-02-26 Gala Design, Inc. Antibody libraries
US20050014932A1 (en) 2003-05-15 2005-01-20 Iogenetics, Llc Targeted biocides
EP1910550A4 (fr) 2005-07-21 2009-11-04 Abbott Lab Expression multigenique comprenant des constructions sorf et methodes faisant appel a des polyproteines, a des pro-proteines, et a une proteolysis
US8685720B2 (en) 2006-11-03 2014-04-01 The Trustees Of Princeton University Engineered cellular pathways for programmed autoregulation of differentiation
WO2013078433A1 (fr) 2011-11-23 2013-05-30 University Of Hawaii Domaines d'auto-traitement pour l'expression de polypeptidiques
EP2848687B1 (fr) 2012-04-27 2017-09-13 JCR Pharmaceuticals Co., Ltd. Nouveau vecteur d'expression
ES2786051T3 (es) 2012-10-25 2020-10-08 Tocagen Inc Vector retroviral con casete de mini-promotor

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990001550A1 (fr) * 1988-07-29 1990-02-22 Zymogenetics, Inc. Translation de haut rendement de messages polycistroniques dans des cellules eucariotiques

Also Published As

Publication number Publication date
EP0598029A4 (en) 1996-04-17
DE69232438T2 (de) 2002-10-10
EP0598029B1 (fr) 2002-02-27
ATE213779T1 (de) 2002-03-15
JPH06509713A (ja) 1994-11-02
DE69232438D1 (de) 2002-04-04
CA2114416A1 (fr) 1993-02-18
WO1993003143A1 (fr) 1993-02-18
JP3378962B2 (ja) 2003-02-17
ES2173082T3 (es) 2002-10-16
EP0598029A1 (fr) 1994-05-25
CA2114416C (fr) 1998-07-07

Similar Documents

Publication Publication Date Title
DK0598029T3 (da) Retrovirale vektorer indeholdende interne ribosome indgangssteder
GR3014924T3 (en) Mammalian expression of the bmp-2 family.
NL1002835A1 (nl) Synergistisch stabilisatormengsel.
FI923280A0 (fi) Aminosubstituerade piperazinderivat.
DE59201430D1 (de) Suchkopfabdeckung für Lenkflugkörper.
DE68905319D1 (de) Herstellung von wasserstoff aus kohlenwasserstoffen.
ES2044950T3 (es) Un procedimiento para producir una proteina.
ES2129487T3 (es) Peptidos sinteticos, anticuerpos dirigidos contra ellos y su utilizacion.
DE69327443D1 (de) Multiplexer, an dessen Eingang mehrere identische Signale verschiedener Phasenlage anliegen
MX18879A (es) Analogos de la prostaglandina de amida heterociclica substituida con 7-oxabicicloheptilo.
ATE423790T1 (de) Synthetische peptide mit il-6 aktivitäthemmung
BR9407693A (pt) Sequência nucleotídica vetor composiçao farmacêutica utilizaçao do vetor e de um composto
GR3021660T3 (en) Anticoagulant peptides
ES2131041T3 (es) Peptidos anticoagulantes.
IT8322114A0 (it) Composti di peptidi sostituiti.
EP0127727A3 (fr) (Omega-(1H-imidazol-1-yl)alkyl)amides N-substitués
EP0179412A3 (fr) Composés peptidiques antigènes
IT8722485A0 (it) Preparazione di composti epossidici a configurazione cis e trans apartire da miscele degli stereoisomeri olefinici corrispondenti.
SE9500901D0 (sv) Miljövänlig tyngd för sportfiske
MX9202871A (es) 5-(amino substituidas)-8-(fenil substituidas)-3h,6h-1,4,5a,8a-tetraazaacenaf-tilen-3-onas.
DE3484304D1 (de) Streptokinase kodierende rekombinante vektoren.
EA199900253A1 (ru) Ptx-чувствительные g-протеины, их получение и применение
JPS6416792A (en) Guanidine related compound containing tetraphenylborate ion, its production and use thereof in peptide synthesis
SE9402253D0 (sv) Process
RU92016315A (ru) Вектор, плазмида, способ получения протеина и метаболита, бактерия, применение бактерии